Development of adenoviral vector-based mucosal vaccine against influenza

Journal of Molecular Medicine

Volumn 89, Issue 4, 2011, Pages 331-341

  Tutykhina, Irina L ^a   Logunov, Denis Y ^a   Shcherbinin, Dmitriy N ^a   Shmarov, Maxim M ^a   Tukhvatulin, Amir I ^a   Naroditsky, Boris S ^a   Gintsburg, Alexander L ^a  

^a GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY   (Russian Federation)

Author keywords

Adenoviral vector; Influenza virus; Nasal vaccines

Indexed keywords

ADENOVIRUS VECTOR; CHEMOKINE; CYTOKINE; HEMAGGLUTININ; IMMUNOGLOBULIN G; INFLUENZA VACCINE; LIVE VACCINE; SECRETORY IMMUNOGLOBULIN;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; B LYMPHOCYTE; CELL MIGRATION; CROSS PROTECTION; CYTOKINE RELEASE; DENDRITIC CELL; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INNATE IMMUNITY; LYMPHOID TISSUE; MACROPHAGE; NONHUMAN; NOSE MUCOSA; NUCLEOTIDE SEQUENCE; PHAGOCYTOSIS; PROTEIN EXPRESSION; RESPIRATORY SYSTEM; REVIEW; T LYMPHOCYTE; TRANSGENE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; GENETIC VECTORS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MUCOUS MEMBRANE; RESPIRATORY SYSTEM; VACCINES, SYNTHETIC;

EID: 79955772885     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-010-0696-0     Document Type: Review

References (119)

1. World Health Organization, Initiative for Vaccine Research Team State of the art of vaccine research and development (2005) http://www.who.int/vaccine- research/documents/en/
2. Ichinohe T, Iwasaki A, Hasegawa H (2008) Innate sensors of influenza virus: clues to developing better intranasal vaccines. Expert Rev Vaccin 7:1435-1445
3. Pires A, Fortuna A, Alves G, Falcão A (2009) Intranasal drug delivery: how, why and what for? J Pharm Pharmaceut Sci 12:288-311
4. Ugwoke M, Agu R, Verbeke N, Kinget R (2005) Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 57:1640-1665 (Pubitemid 41443473)
5. Jadhav KR, Gambhire MN, Shaikh IM, Kadam VJ, Pisal SS (2007) Nasal Drug Delivery System-Factors Affecting and Applications. Curr Drug Ther 2:27-38 (Pubitemid 46723136)
6. Medaglini D, Ciabattini A, Cuppone AM, Costa C, Ricci S, Costalonga M, Pozzi G (2006) In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii. Infect Immun 5:2760-2766 (Pubitemid 43672985)
7. Kopecky-Bromberg SA, Palese P (2009) Recombinant vectors as influenza vaccines. Curr Top Microbiol Immunol 333:243-267
8. Mainardes RM, UrbanMC, Cinto PO, ChaudMV, Evangelista RC, Gremião MP (2006) Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery. Curr Drug Deliv 3:275-85 (Pubitemid 44031626)
9. Hobson P, Barnfield C, Barnes A, Klavinskis LS (2003) Mucosal immunization with DNA vaccines. Methods 31:217-224 (Pubitemid 37162794)
10. Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, Feldmann H, Wilson JM, Kobinger GP (2007) Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis 196(Suppl 2):S413-S420 (Pubitemid 351417289)
11. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51:81-96 (Pubitemid 32763074)
12. Shirakawa T (2009) Clinical trial design for adenoviral gene therapy products. Drug News Perspect 22:140-145
13. Mestecky J, Lamm M, McGhee J, Bienenstock J, Mayer L, Strober W (2005) Mucosal Immunology. Elsevier/Academic Press, Amsterdam
14. Wijburg O, Uren T, Simpfendorfer K, Johansen F, Brandtzaeg P, Strugnell R (2006) Innate secretory antibodies protect against natural Salmonella typhimurium infection. J Exp Med 203:21-26 (Pubitemid 43139640)
15. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197-216. (Pubitemid 34293424)
16. Pichlmair A, Schulz O, Tan C, Näslund T, Liljeström P, Weber F, Reis E, Sousa C (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 314:997-1001. (Pubitemid 44749946)
17. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann K, Schlee M et al (2006) 5'- Triphosphate RNA is the ligand for RIG-I. Science 314:994-997
18. Diebold S, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529-1531 (Pubitemid 38314425)
19. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R, Chignard M, Si-Tahar M (2006) Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virusinduced acute pneumonia. PLoS Pathog 2:e53
20. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, Si-Tahar M (2005) Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280:5571-5580 (Pubitemid 40280035)
21. Wang JP, Bowen GN, Padden C, Cerny A, Finberg RW, Newburger PE, Kurt-Jones EA (2008) Toll-like receptormediated activation of neutrophils by influenza A virus. Blood 112:2028-2034
22. Theofilopoulos A, Baccala R, Beutler B, Kono D (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307-336 (Pubitemid 40563172)
23. Fujisawa H (2001) Inhibitory role of neutrophils on influenza virus multiplication in the lungs of mice. Microbiol Immunol 45:679-688 (Pubitemid 33027211)
24. Ratcliffe DR, Nolin SL, Cramer EB (1988) Neutrophil interaction with influenza-infected epithelial cells. Blood 72(1):142-149
25. Fujisawa H, Tsuru S, Taniguchi M, Zinnaka Y, Nomoto K (1987) Protective mechanisms against pulmonary infection with influenza virus. I. Relative contribution of polymorphonuclear leukocytes and of alveolar macrophages to protection during the early phase of intranasal infection. J Gen Virol 68:425-432. (Pubitemid 17007829)
26. Yamamoto K, Miyoshi-Koshio T, Utsuki Y, Mizuno S, Suzuki K (1994) Virucidal activity and viral protein modification by myeloperoxidase: a candidate for defense factor of human polymorphonuclear leukocytes against influenza virus infection. J Infect Dis 164:8-14
27. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI (1985) Defensins. Natural peptide antibiotics of human neutrophils. J Clin Investig 76:1427-1435 (Pubitemid 16193690)
28. Smith JA (1994) Neutrophils, host defense, and inflammation: a double edged sword. J Leukoc Biol 56:672-686
29. Sibille Y, Reynolds HY (1990) Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 141:471-501 (Pubitemid 20068893)
30. Hofmann P, Sprenger H, Kaufmann A, Bender A, Hasse C, Nain M, Gemsa D (1997) Susceptibility of mononuclear phagocytes to influenza A virus infection and possible role in the antiviral response. J Leukoc Biol 61:408-414 (Pubitemid 27219833)
31. Kaufmann A, Salentin R, Meyer RG, Bussfeld D, Pauligk C, Fesq H, Hofmann P, Nain M, Gemsa D, Sprenger H (2001) Defense against influenza A virus infection: essential role of the chemokine system. Immunobiology 204:603-613 (Pubitemid 34134174)
32. Leung K, Ada G (1981) Induction of natural killer cells during murine influenza virus infection. Immunobiology 160:352-366 (Pubitemid 12214166)
33. Stein-Streilein J, Bennett M, Mann D, Kumar V (1983) Natural killer cells in mouse lung: surface phenotype, target preference, and response to local influenza virus infection. J Immunol 131:2699-2704 (Pubitemid 14208817)
34. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409 (6823):1055-1060 (Pubitemid 32204059)
35. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O (2001) Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 31:2680-2689 (Pubitemid 32898735)
36. Gazit R, Gruda R, Elboim M, Arnon TI, Katz G, Achdout H, Hanna J, Qimron U, Landau G, Greenbaum E et al (2006) Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 7:517-523
37. Biron C, Nguyen K, Pien G, Cousens L, Salazar-Mather T (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189-220 (Pubitemid 29241123)
38. Takahashi I, Nochi T, Yuki Y, Kiyono H (2009) New horizon of mucosal immunity and vaccines. Curr Opin Immunol 21:352-358
39. Male D, Brostoff J, Roth DB, Roitt I (2006) Immunology. Mosby Elsevier, Philadelphia
40. van Ginkel FW, Nguyen HH, McGhee JR (2000) Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis 6:123-132 (Pubitemid 30226889)
41. Briskin MJ, McEvoy LM, Butcher EC (1993) MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1. Nature 363:461-464 (Pubitemid 23179394)
42. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC (1993) Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 74:185-195 (Pubitemid 23219889)
43. Sun K, Johansen FE, Eckmann L, Metzger DW (2004) An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J Immunol 173:4576-4581 (Pubitemid 39280690)
44. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, Shimada S, Nanno M, Matsuoka Y, Ohwaki M et al (2002) Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvantcombined vaccines. J Immunol 168:2930-2938 (Pubitemid 34211673)
45. Kreijtz JH, Bodewes R, Van Den Brand JM, de Mutsert G, Baas C, van Amerongen G, Fouchier RA, OsterhausAD, Rimmelzwaan GF (2009) Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 27:4983-4989
46. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82:5161-5166 (Pubitemid 351705225)
47. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H (2003) Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21:3212-3218 (Pubitemid 36700428)
48. Tamura S, Kurata T (2004) Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 57:236-247 (Pubitemid 40260238)
49. Tripathy SK, Black HB, Goldwasser E, Leiden JM (1996) Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replicationdefective adenovirus vectors. Nat Med 2:545-550
50. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z (2004) Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173:6357-6365 (Pubitemid 39487795)
51. Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP (2009) Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS ONE 4:e5308
52. Li WH, Zhang Y, Wang SH, Liu L, Yang F (2003) Recombinant replication-defective adenovirus based rabies vaccine. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 25:650-654
53. Lees CY, Briggs DJ, Wu X, Davis RD, Moore SM, Gordon C, Xiang Z, Ertl HC, Tang DC, Fu ZF (2002) Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoprotein. Vet Microbiol 85:295-303 (Pubitemid 34164656)
54. Santosuosso M, McCormick S, Xing Z (2005) Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 18:283-291 (Pubitemid 41106007)
55. Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, Nabel GJ (2007) Mechanism of AD5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 3: e25
56. Johansson C, Jonsson M, Marttila M, Persson D, Fan XL, Skog J, Frängsmyr L, Wadell G, Arnberg N (2007) Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells. J Virol 81:954-963 (Pubitemid 46067920)
57. Jooss K, Chirmule N (2003) Immunity to adenovirus and adenoassociated viral vectors: implications for gene therapy. Gene Ther 10:955-963 (Pubitemid 36722430)
58. Hartman ZC, Appledorn DM, Amalfitano A (2008) Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132:1-14 (Pubitemid 351232078)
59. Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, Rodgers JR, Lee B (2007) Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 15:378-385 (Pubitemid 46111889)
60. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, Zhou D, Lin SW, Bian A, Xiang ZQ, Iparraguirre A et al (2007) Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110:1916-1923 (Pubitemid 47443905)
61. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574-1583 (Pubitemid 29465516)
62. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL (2009) Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27:6512-6521
63. Park KS, Lee J, Ahn SS, Byun YH, Seong BL, Baek YH, Song MS, Choi YK, Na YJ, Hwang I et al (2009) Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Virology 395:182-189
64. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK, Sambhara S (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367:475-481 (Pubitemid 43208903)
65. Hoelscher MA, Jayashankar L, Garg S, Veguilla V, Lu X, Singh N, Katz JM, Mittal SK, Sambhara S (2007) New pre-pandemic influenza vaccines: an egg-and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin Pharmacol Ther 82:665-671 (Pubitemid 350114832)
66. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC (2005) Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029-1036 (Pubitemid 40037652)
67. ClinicalTrials.gov. A service of the U. S. National Institutes of Health. Safety and Immunogenicity Study of Adenovirus-Vectored, Intranasal Pandemic Influenza Vaccine.http://clinicaltrials.gov/ct2/ show/study/NCT00755703?term= adenovirus&rank=9)
68. Tang DC, Zhang J, Toro H, Shi Z, Van Kampen KR (2009) Adenovirus as a carrier for the development of influenza virusfree avian influenza vaccines. Expert Rev Vaccin 8:469-481
69. Thacker EE, Timares L, Matthews QL (2009) Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccin 8:761-777
70. Goossens PH, Vogels R, Pieterman E, Havenga MJ, Bout A, Breedveld FC, Valerio D, Huizinga TW (2001) The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue. Arthritis Rheum 44:48-52 (Pubitemid 32113117)
71. Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ, Zamarron C, Dichek DA (1997) Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 99:209-219 (Pubitemid 27053989)
72. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A (2004) Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11:351-357 (Pubitemid 38380817)
73. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR et al (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81:4654-4663 (Pubitemid 46668663)
74. Croyle MA, Yu QC, Wilson JM (2000) Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther 11:1713-1722
75. Croyle MA, Chirmule N, Zhang Y, Wilson JM (2002) PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 13:1887-1900 (Pubitemid 35292683)
76. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW (2001) Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 8:341-348 (Pubitemid 32241933)
77. Beer SJ, Matthews CB, Stein CS, Ross BD, Hilfinger JM, Davidson BL (1998) Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther 5:740-746 (Pubitemid 28321007)
78. Stone D, Ni S, Li ZY, Gaggar A, DiPaolo N, Feng Q, Sandig V, Lieber A (2005) Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol 79:5090-5104 (Pubitemid 40464259)
79. Bangari DS, Mittal SK (2006) Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 6:215-226
80. Segura MM, Alba R, Bosch A, Chillón M (2008) Advances in helper-dependent adenoviral vector research. Curr Gene Ther 8:222-235
81. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, Feldmann H, Kobinger GP (2008) Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3:e3548
82. Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, Feldmann H, Wilson JM, Kobinger GP (2007) Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis 196:413-420
83. Lo CY, Wu Z, Misplon JA, Price GE, Pappas C, Kong WP, Tumpey TM, Epstein SL (2008) Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: coldadapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26:2062-2072
84. Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, Nason M, Andersen H, Tumpey TM, Nabel GJ (2010) Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS ONE 5:e9812
85. Tumpey TM, Renshaw M, Clements JD, Katz JM (2001) Mucosal delivery of inactivated influenza vaccine induces Bcell- dependent heterosubtypic crossprotection against lethal influenza A H5N1 virus infection. J Virol 75:5141-5150 (Pubitemid 32448536)
86. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H et al (2003) Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21:3212-3218 (Pubitemid 36700428)
87. Quan FS, Compans RW, Nguyen HH, Kang SM (2008) Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 82:1350-1359
88. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J (2001) Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 183:368-376 (Pubitemid 32105595)
89. Toro H, Tang DC, Suarez DL, Zhang J, Shi Z (2008) Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine. Vaccine 26:2640-2646
90. Smirnov YA, Lipatov AS, Gitelman AK, Claas EC, Osterhaus AD (2000) Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol 145:1733-1741
91. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M et al (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265-273
92. Throsby M, Van Den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y et al (2008) Heterosubtypic neutralizing monoclonal antibodies crossprotective against H5N1 and H1N1 recovered from human IgM + memory B cells. PLoS ONE 3:e3942
93. Russell RJ, Gamblin SJ, Haire LF, Stevens DJ, Xiao B, Ha Y, Skehel JJ (2004) H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. Virology 325:287-296 (Pubitemid 38902794)
94. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA (2009) Structural and functional bases for broadspectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265-273
95. Throsby M, Van Den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM + memory B cells. PLoS ONE 3:e3942
96. Shmarov MM, Sedova ES, Verkhovskaya LV, Rudneva IA, Bogacheva EA, Baryikova YA, Shcherbinin DN, Lysenko AA, Tutykhina IL, Logunov DY et al (2010) Induction of a protective heterosubtypic immune response against the influenza virus by using recombinant adenoviral vectors expressing hemagglutinin of the influenza H5 virus. Acta Naturae 1:119-126
97. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM et al (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13:426-435 (Pubitemid 46348126)
98. Sekine S, Kataoka K, Fukuyama Y, Adachi Y, Davydova J, Yamamoto M, Kobayashi R, Fujihashi K, Suzuki H, Curiel DT et al (2008) A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngealassociated lymphoreticular tissue dendritic cell migration. J Immunol 180:8126-8134
99. Xing Z, McFarland CT, Sallenave JM, Izzo A, Wang J, McMurray DN (2009) Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS ONE 4:e5856
100. Ronan EO, Lee LN, Tchilian EZ, Beverley PC (2010) Nasal associated lymphoid tissue (NALT) contributes little to protection against aerosol challenge with Mycobacterium tuberculosis after immunisation with a recombinant adenoviral vaccine. Vaccine 28:5179-5184
101. Lobanova LM, Baig TT, Tikoo SK, Zakhartchouk AN (2010) Mucosal adenovirus-vectored vaccine for measles. Vaccine. doi:10.1016/j.vaccine.2010.09. 055
102. Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, Lien PS, Le QM, Kawaoka Y (2007) Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog 3:1374-1379 (Pubitemid 350085602)
103. Lodes MJ, Suciu D, Wilmoth JL, Ross M, Munro S, Dix K, Bernards K, Stöver AG, Quintana M, Iihoshi N, Lyon WJ, Danley DL, McShea A (2007) Identification of upper respiratory tract pathogens using electrochemical detection on an oligonucleotide microarray. PLoS ONE 2:e924
104. Couceiro JN, Paulson JC, Baum LG (1993) Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium: the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res 29:155-165 (Pubitemid 23235070)
105. Diaz F, Gravotta D, Deora A, Schreiner R, Schoggins J, Falck- Pedersen E, Rodriguez-Boulan E (2009) Clathrin adaptor AP1B controls adenovirus infectivity of epithelial cells. Proc Natl Acad Sci USA 106:11143-11148
106. Chen C, Zhuang X (2008) Epsin 1 is a cargo-specific adaptor for the clathrin-mediated endocytosis of the influenza virus. Proc Natl Acad Sci USA 105:11790-11795
107. Varga MJ, Weibull C, Everitt E (1991) Infectious entry pathway of adenovirus type 2. J Virol 65:6061-6070.
108. Szretter KJ, Gangappa S, Belser JA, Zeng H, Chen H, Matsuoka Y, Sambhara S, Swayne DE, Tumpey TM, Katz JM (2009) Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol 83:5825-5834
109. Fejer G, Drechsel L, Liese J, Schleicher U, Ruzsics Z, Imelli N, Greber UF,Keck S,Hildenbrand B,KrugA, Bogdan C, Freudenberg MA (2008) Key role of splenic myeloid DCs in the IFN-a/ß response to adenoviruses in vivo. PLoS Pathog 4:e1000208
110. Schnell MA, ZhangY TJ, Gao GP, Yu QC, Qian R, Chen SJ, Varnavski AN, LeClair C, Raper SE, Wilson JM (2001) Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 3:708-722 (Pubitemid 32509868)
111. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ (2002) The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther 13:129-141 (Pubitemid 34075177)
112. Muruve DA, Barnes MJ, Stillman IE, Libermann TA (1991) Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10:965-976
113. Otake K, Ennist DL, Harrod K, Trapnell BC (1998) Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther 9:2207-2222 (Pubitemid 28498007)
114. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramírez P,Martin-Loeches I, Varillas D, GallegosMC, Serón C et al (2009) Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 13:R201
115. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z (2004) Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173:635763-635765
116. Hashimoto M, Boyer JL, Hackett NR, Wilson JM, Crystal RG (2005) Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun 73:6885-6891 (Pubitemid 41368857)
117. Guo L, Wang J, Zhou H, Si H, Wang M, Song J, Han B, Shu Y, Ren L, Qu J, Hung T (2008) Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice. Vaccine 26:460-468
118. Wiley JA, Hogan RJ, Woodland DL, Harmsen AG (2001) Antigen-specific CD8+ T cells persist in the upper respiratory tract following influenza infection. J Immunol 167:3293-3299 (Pubitemid 32852570)
119. Mora JR, von Andrian UH (2008) Differentiation and homing of IgA-secreting cells. Mucosal Immunol 1:96-109